DUBAI, UAE, Nov. 7, 2025 /PRNewswire/ — Mantle, the high-performance distribution and liquidity layer for real-world assets (RWAs), together with Bybit and Backed, today announced its strategic collaboration to bring tokenized U.S. equities onchain through xStocks, enabling 24/7 access to leading global assets directly within the Mantle ecosystem.

Through xStocks, users can gain exposure to tokenized versions of leading equities such as NVDAx, AAPLx, and MSTRx, seamlessly connecting traditional financial assets with the composability of decentralized finance. The collaboration combines Mantle’s scalable blockchain infrastructure, Bybit’s global exchange liquidity, and Backed’s regulated tokenization framework to deliver a fully onchain experience for traditional markets.

Seamless Integration Between CEX and DeFi

At launch, Bybit will provide full support for deposits and withdrawals of xStocks via Mantle, allowing users to move assets between Bybit and Mantle Network efficiently and securely. This direct CEX-to-chain bridge simplifies onboarding, drives liquidity, and opens new opportunities for both users and developers to engage with tokenized markets.

xStocks tokens, issued by Backed in partnership with regulated custodians, are fully backed 1:1 by their underlying securities. Each token mirrors a specific equity or treasury asset, offering transparent, verifiable, and programmable exposure to leading global companies.

“Tokenized equities are redefining how traditional markets interact with blockchain technology,” said Emily Bao, Head of Spot at Bybit. “Bybit is proud to support Mantle’s vision of creating a unified, scalable platform where real-world assets can thrive onchain, delivering accessible and innovative financial solutions to a global audience.”

Building the Infrastructure for Onchain Capital Markets

This integration marks a major milestone for Mantle, Ethereum’s largest ZK proof-powered L2 network. Combining a modular architecture, advanced data availability layer, and low-fee environment, Mantle enables secure, scalable and cost-efficient access to tokenized equities, seamlessly converging TradFi, CeFi and DeFi within a unified onchain framework.

On Mantle, tokenized equities are more than digital representations, they become programmable financial primitives. Builders and developers can leverage these assets to design innovative instruments, integrate real-world and crypto assets into automated strategies, and optimize capital efficiency across ecosystems.

“With Mantle’s modular architecture, premium technology stack, and Ethereum-grade security, combined with Bybit’s infrastructure and reach, tokenized equities are set to become a foundational building block for the next wave of onchain finance,” said Emily Bao, Key Advisor at Mantle. “xStocks represents a pivotal step in turning traditional assets into composable building blocks that scale across Mantle’s ecosystem and power the decentralized economy.”

“It takes more than tokenization to bridge TradFi and DeFi; you need infrastructure and distribution,” added David Henderson, Head of Growth at Backed. “Beyond accessibility, xStocks are built for composability. Together with Mantle and Bybit, we’re building the onchain economy to not only absorb capital markets but improve them.”

Driving Mantle’s Broader RWA Momentum

This collaboration builds on Bybit’s continued support for Mantle’s expanding RWA ecosystem, following recent initiatives such as:

• Anchorage integration, providing institutional-grade custody for $MNT to expand global access.
• Moomoo Exchange listing, bringing $MNT to U.S. retail investors alongside stocks, ETFs, and crypto.
• Tokenization-as-a-Service (TaaS), offering institutions a compliant, end-to-end framework to tokenize and scale real-world assets on Mantle.
• RWA Hackathons & Scholarships launch, fostering innovation and empowering talent pipelines to accelerate compliant tokenization and institutional adoption.

Advancing Mantle’s Vision for Tokenized Markets

As Mantle continues building the premier liquidity and distribution layer for tokenized assets, this initiative aligns with Mantle’s broader roadmap to expand RWA integrations, unlocking new capital efficiencies and composable DeFi strategies across its ecosystem.

The collaboration reinforces Mantle’s commitment to enabling open, secure, and scalable access to tokenized assets, paving the way for broader participation in the trillion-dollar global capital markets through blockchain technology.

xStocks are not available in the U.S. or to U.S. citizens. Geographic restrictions apply.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with onchain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.

For more information about Mantle, please visit: mantle.xyz

For more social updates, please follow: Mantle Official X & Mantle Community Channel  

About Backed

Founded in 2021, Backed is the leading issuer of compliant tokenized equities and ETFs, including the innovative xStocks line of products. Backed’s products are freely transferable  ERC-20 and SPL tokens compatible with Ethereum and Solana-based platforms. For more information, please visit https://backed.fi/

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media 

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

HANGZHOU, China, Nov. 7, 2025 /PRNewswire/ — The China (Hangzhou) Art and Technology Biennale opened at Yuhang Art Museum, Hangzhou on October 18. It is initiated by the China Academy of Art (CAA) and curated by the CAA School of Design & Innovation and CAA Art Museum. As a key part of the 3rd Liangzhu Forum, the biennale gathers works by over 160 creators from more than 20 countries and regions, displaying the reconstruction trajectory and future prospects of cultural ecology amid technological iteration.

This biennale is deeply rooted in the disciplinary foundation of the CAA. The Design Studies of CAA adheres to the academic principle of “integrating Eastern and Western cultures” and “innovating from tradition”, leading the establishment and development of modern design disciplines in China. Over the years, its achievements have been the forefront and pinnacle of Chinese design education. The CAA has put forward the academic proposition of “Eastern Design Studies”, and centered on the development strategy of “Driven by Global and Domestic Vision and Empowered by Culture and Tech Education”. Featuring “Design Humanities” and “Art-Technology Integration”, it has grown into China’s largest, most well-structured design education cluster covering the broadest range of social and industrial needs. With the School of Design & Innovation at the forefront of disciplinary expansion, CAA has been developing cutting-edge, and interdisciplinary innovative design disciplines. It also actively promotes integrated design innovation based on society and industry, and strives to build a “New Bauhaus” and “Vkhutemas” for the era of big data and intelligent media.

This biennale is also inspired by the unique regional culture of Liangzhu in Hangzhou. Liangzhu is the archaeological evidence of China’s 5,000-year-old civilization; Hangzhou is not only a famous historical city but also a city of innovation and vitality. Here, ancient civilization and modern technology shine together, serving as a vivid interpretation of the cultural strength of Chinese modernization. This biennale gathers global cutting-edge creations and innovative ideas, continuously influencing industry, education, society, innovation, and other fields. It has become a key hub connecting local wisdom with the global context, making the “Hangzhou Model” a vivid example of the deep integration of culture and technology.

The fundamental mission of art and science is to “discover the world and discover humanity”. Through four sections —”Connections: Embodied Interaction”, “Symbiosis: Digital Education”, “Speculation: Ecological Reconstruction”, and “Manifesto: Philosophical Inquiry” — the biennale constructs a narrative framework of “Heaven, Earth, Human, and Machine”. The first section allows visitors to experience the connections between humans, machines, and the world through embodied interactions. The second section focuses on promoting the coexistence of humanities and technology through digital education. The third section encourages visitors to speculate on how technology and environment can interact. The final section prompts reflections on the values and ethical boundaries of art-technology integration. These explorations not only continue the century-old academic tradition of CAA, but also demonstrate China’s unique approach to engaging in civilizational dialogue amid the wave of globalization.

In the future, CAA will continue to build distinctive, future-oriented and world-class design studies, providing a more comprehensive “CAA solution” for global design education. The China (Hangzhou) Art and Technology Biennale, emerging from this context, will build bridges of dialogue between Liangzhu and the world, between art and technology, allowing ancient wisdom and cutting-edge exploration to resonate in harmony, while enabling artistic intelligence and technological futures to illuminate each other.

The exhibition is curated by Duan Weibin, the dean of the CAA’s School of Design&Innovation. The article is also written by Duan Weibin.

LEWES, Del., Nov. 7, 2025 /PRNewswire/ — HiBy has officially launched its new flagship portable HiFi player, RS8 II, on October 30, 2025. The RS8 II integrates HiBy’s advanced technologies in portable audio with deep insights into market trends, redefining high-end portable music players. It features a high-performance processor, upgraded audio architecture, and multiple connectivity options, supporting high-resolution audio formats and versatile output, providing users with a complete digital audio experience and flexible connectivity.

“HIBY RS8 II : the Evolution of RS Series”

The player is powered by the Qualcomm Dragonwing QCS8550 (8Gen2 platform) and the upgraded third-generation DARWIN audio architecture, paired with AdaptiveAMP, offering dynamic A/B-class amplification with 64-level adjustability and THD+N as low as 0.0008%. Its powerful CPU+GPU+NPU+FPGA+DSP array combined with a precisely matched R2R resistor network ensures accurate high-resolution audio reproduction. Sankofa AI tonality simulation allows users to enjoy sound signatures modeled after classic audio sources such as MD, CD, cassette, and reel-to-reel tape players, with free updates for a personalized HiFi experience.

In terms of design, the RS8 II adopts a unibody aluminum chassis with a glass back, geometric lines, and three-dimensional cuts for a distinctive appearance. The rear panel is engraved with RS and “DESIGNED BY HIBY,” hexagonal side buttons symbolize the Darwin architecture, and the multi-faceted rotary knob reflects light like a diamond. At 425g, the player balances flagship-level performance with portability.

The RS8 II features a 5.5-inch 1080×1920 HD display and a 46.8Wh battery supporting up to 80W PD3.0 fast charging. Wireless connectivity includes Wi-Fi 7 MIMO and Bluetooth 5.3 (compatible with AptX Adaptive & AptX Lossless). Audio performance is enhanced by 45.1584MHz and 49.152MHz NDK femtosecond oscillators, supporting DSD1024, PCM 1536kHz/32bit, and MQA 16X, and Direct Transport Audio (D.T.A.), which bypasses Android system SRC for high-resolution playback from third-party apps. Output options include 3.5mm PO/LO combo, 4.4mm BAL Phone-out, 4.4mm BAL Line-out, Type-C digital audio supporting SPDIF coaxial, USB Audio In/Out, and the first-time portable player I²S interface, greatly expanding connectivity possibilities.

With its advanced tonality simulation, ultra-low distortion, and efficient power management, the RS8 II delivers an unprecedented high-fidelity listening experience, establishing a new benchmark for portable HiFi.

About HiBy

Founded in 2011, HiBy is a leading authority in portable audio, specializing in the development, design, and sales of top-tier portable audio products through its subsidiaries HiBy Music and HiBy Digital.

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery

SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ — Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit’s AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development.

Lunit and CellCarta presented a comparative analysis demonstrating that AI can standardize tumor immune phenotyping across multiple cancer types, including non-small cell lung, colorectal, and urothelial cancers. When assessing tumor and stromal segmentation, Lunit SCOPE IO showed high concordance with pathologist assessments based on traditional immunohistochemistry (Spearman’s correlation coefficients of 0.91 and 0.86). Threshold calibration improved alignment between the AI-based and pathologist scoring of inflamed, excluded, and desert immune phenotypes and improved its reliability and reproducibility. These results position Lunit SCOPE IO as a scalable solution for immune profiling, reducing reliance on additional IHC staining and enabling consistent analysis of the tumor immune microenvironment in both research and clinical practice.

Lunit also introduced new data showcasing the utility of Lunit SCOPE uIHC, the company’s AI-powered quantitative IHC platform, in mapping spatial interactions between tumor-infiltrating lymphocytes (TILs) and 74 membrane-specific protein targets currently in development for antibody-based therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs). Analyzing over 47,000 IHC images across 34 cancer types, the study revealed that while most protein targets showed decreased TIL density within expression regions, select proteins such as PD-L1 and TNFRSF4, displayed positive spatial correlation with lymphocyte infiltration. Notably, FGFR4 expression was linked to increased intra-tumoral lymphocytes in colorectal, non-squamous lung, and uterine cancers, suggesting its potential as a BiTE target. The findings demonstrate how Lunit SCOPE uIHC can integrate spatial immune context into early drug discovery workflows, accelerating the identification and validation of therapeutic targets.

In another research, Lunit presented new data confirming the predictive power of AI-based spatial profiling in MET-mutated non-small cell lung cancer (NSCLC), demonstrating how AI-powered image-based profiling can uncover immunologically active subtypes within cancers.

“At SITC 2025, we’re showcasing how our digital pathology AI, the Lunit SCOPE suite, can bridge research and real-world clinical practice,” said Brandon Suh, CEO of Lunit. “From identifying immunotherapy-responsive subtypes to guiding antibody-based drug discovery, our AI technology is redefining how we understand and target the tumor–immune interface. Collaborations like ours with CellCarta are key to unlocking the full potential of this transformation.”

Lunit’s featured studies at SITC 2025 include:

• Poster Presentation [#1347]: AI-powered image-based spatial profiling of MET-mutated non-small cell lung cancer identifies immune-active MET exon 14 skipping subtypes as potential immunotherapy targets, Zachary Wallen, Labcorp Oncology
• Poster Presentation [#1264]: Artificial Intelligence-Powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotypes in H&E Stained Non-Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer, Elizabeth Ross, CellCarta
• Poster Presentation [#1098]: Unveiling spatial correlation between cell surface targets and lymphocytes via artificial intelligence (AI)-powered quantitative immunohistochemistry (IHC) analysis, Sukjun Kim, Lunit

Visit Lunit at booth #818 to learn more about the company’s latest innovations in AI-powered digital pathology and oncology research.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Following the integration of Volpara, Lunit now offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while Lunit SCOPE platform is used in research partnership with global pharma leaders for biomarker development and companion diagnostics.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.

VICTORIA, Seychelles, Nov. 7, 2025 /PRNewswire/ — Bitget, the world’s largest Universal Exchange (UEX), today announced a limited-time 90% reduction in stock futures trading fees, marking one of the most aggressive pricing initiatives ever launched by a major digital asset platform.

The promotion arrives as U.S. equity markets surge on the back of the AI-driven bull run, creating what Bitget describes as a “rare window of volatility and opportunity” for traders worldwide. Under the campaign, all stock futures trading pairs on Bitget will feature ultra-low fees of just 0.0065%, making it significantly cheaper than comparable offerings on traditional CFD platforms.

The announcement follows record activity on Bitget’s platform, where the stock-futures segment recently exceeded $300 million in single-day trading volume, highlighting the rapid adoption of tokenized-equity products and institutional-grade derivatives among global users.

“This earnings season is one of the most dynamic in years,” said Gracy Chen, CEO of Bitget. “With technology stocks leading global momentum, we want our users to seize these opportunities with institutional-grade efficiency and minimum cost barriers. This 90% fee reduction puts professional-level access into the hands of every trader.”

The campaign reflects Bitget’s long-term commitment to its Universal Exchange (UEX) vision — creating a unified platform where users can seamlessly access both crypto-native and traditional financial products under one account. By bridging tokenized assets and traditional markets, Bitget continues to make global investing more transparent, accessible, and cost-efficient.

This initiative also reinforces Bitget’s positioning as one of the few exchanges that successfully integrates crypto futures, tokenized equities, and AI-driven trading tools into a single ecosystem. With ultra-competitive fees, Bitget aims to attract both retail and institutional users seeking diversified exposure during a pivotal market cycle.

“Our mission is simple — make global financial participation frictionless,” added Gracy Chen, CEO of Bitget. “By bringing stock futures, crypto markets, and advanced AI tools into one platform, Bitget is helping traders navigate the Universal Exchange era with speed, data, and confidence.”

The 90% fee reduction is available for a limited time and coincides with the peak of the earnings season, when trading volumes and volatility traditionally spike. Bitget expects the campaign to further accelerate adoption of its stock futures products and onboard a new generation of multi-asset traders.

About Bitget

Established in 2018, Bitget is the world’s leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World’s Top Football League, LALIGA, in EASTERN, SEA and LATAM markets. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Late-breaking poster presentations show HCB101’s favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy

TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland. Both datasets were accepted for late-breaking poster presentations, highlighting the program’s potential impact on innate immune checkpoint blockade.

HCB101’s progress reflects its distinct engineering compared to earlier CD47-targeting approaches. First-generation CD47 antibodies, such as magrolimab and lemzoparlimab, demonstrated clinical activity but faced significant safety or efficacy challenges, leading to discontinuations or halted collaborations. Second-generation wild-type SIRPα fusions, such as maplirpacept (TTI-622), improved safety but did not deliver sufficient efficacy in solid tumors, limiting their adoption. IgG1-based fusions attempted to boost immune activation but triggered excessive Fcγ-mediated toxicity and poor tolerability, restricting their use mainly to hematologic malignancies. Third-generation engineered SIRPα fusions with inactivated IgG1 Fc improved safety in combinations but showed limited standalone efficacy. 

“The acceptance of two late-breaking abstracts at SITC for HCB101 monotherapy and combination therapy, along with our earlier preclinical abstract for HCB301, a tri-specific fusion targeting SIRPα/CD47, PD-1/PD-L1, and TGFβ, reinforces the scientific breadth of our platform across innate and adaptive immunity,” said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. “HCB101 was purposely engineered to overcome the cytopenias seen with first-generation anti-CD47 antibodies while maintaining potent immune activation. In second-line gastric cancer, the combination of HCB101 with standard-of-care therapy achieved a 100% confirmed response rate in the active-dose cohort, far exceeding the 28% ORR benchmark from the RAINBOW trial. These results position HCB101 not just as a safer SIRPα-CD47 backbone, but as a next-generation macrophage checkpoint immunotherapy with best-in-class potential.”

Late-Breaking Abstract Highlights (Data as of August 2025)

1. HCB101-101 Monotherapy Study (NCT05892718)

Title: HCB101, a Next-Generation Fc-Engineered SIRPα-CD47 Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity in Advanced Cancers

• In the ongoing Phase 1a dose-escalation, no dose-limiting toxicities (DLTs) have been observed at doses up to 24 mg/kg.
• CD47 receptor occupancy ≥99% achieved at doses ≥5 mg/kg, with dose-proportional pharmacokinetics.
• Confirmed partial responses seen in head and neck squamous cell carcinoma (HNSCC) and marginal zone lymphoma (MZL).
• Several patients achieved stable disease, with progression-free survival up to 32 weeks.

2. HCB101-201 Combination Therapy Study (NCT06771622)

Title: Phase 1b/2a Study of HCB101 Combined with Standard Therapies Demonstrates Manageable Safety and Dose-Dependent Antitumor Activity in Immunologically Cold Advanced Solid Tumors

• In second-line gastric cancer (GC):
  • 100% confirmed partial response rate (6/6 evaluable patients) at active doses when combined with ramucirumab and paclitaxel.
  • Tumor shrinkage up to 78%, surpassing the ~26.5% ORR benchmark from RAINBOW.
• In first-line triple-negative breast cancer (TNBC):
  • Confirmed partial response with 73% tumor reduction at the effective dose.
• Safety was manageable and consistent with the cytopenia-sparing design, with only minimal hematologic effects observed.

Dr. Fangling Ning, Investigator from the Affiliated Hospital of Binzhou Medical University, commented, “What’s unique about HCB101 is that it avoids the cytopenias that plagued anti-CD47 antibodies by minimizing red blood cell binding, while still engaging CD47 strongly on tumor cells. In our gastric cancer cohort, the responses at active doses are encouraging in a patient population that historically has had limited options. These findings validate HCB101’s unique design and suggest meaningful potential in immunologically cold tumors.”

About HCB101: A Differentiated CD47-SIRPα Blockade

HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging. Key differentiators of HCB101:

• Enhanced safety: Cytopenia-sparing profile, with no DLTs observed up to 30 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window.
• Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
• Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, TNBC, HNSCC, non-Hodgkin lymphoma, and ovarian cancer.
• Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in 2L gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in 1L TNBC and 2L HNSCC, substantially exceeding historical benchmarks.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite the landscape of cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs in multi-functional, innovative molecular configurations in R&D and improving CMC manufacturing processes, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: https://www.hanchorbio.com